Preoperative Molecular Markers in Thyroid Nodules
The need for distinguishing benign from malignant thyroid nodules has led to the pursuit of differentiating molecular markers. The most common molecular tests in clinical use are Afirma® Gene Expression Classifier (GEC) and Thyroseq® V2. Despite the rapidly developing field of molecular markers, sev...
Main Authors: | Zeyad T. Sahli, Philip W. Smith, Christopher B. Umbricht, Martha A. Zeiger |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-04-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fendo.2018.00179/full |
Similar Items
-
Molecular Testing for Thyroid Nodules: The Experience at McGill University Teaching Hospitals in Canada
by: Mohannad Rajab, et al.
Published: (2022-08-01) -
Molecular Tests for Risk-Stratifying Cytologically Indeterminate Thyroid Nodules: An Overview of Commercially Available Testing Platforms in the United States
by: Michiya Nishino, et al.
Published: (2021-05-01) -
Indeterminate thyroid nodules in the era of molecular genomics
by: Sarika N. Rao, et al.
Published: (2020-09-01) -
A Multi-institutional Study of Prevalence and Clinicopathologic Features of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP) in Korea
by: Ja Yeong Seo, et al.
Published: (2019-11-01) -
BRAFV600E and TERT promoter C228T mutations on ThyroSeq v3 analysis of delayed skin metastasis from papillary thyroid cancer: a case report and literature review
by: Jee-Hye Choi, et al.
Published: (2023-02-01)